Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.
Status:
Terminated
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Study title: A multicentre double-blind, placebo-controlled, randomised, parallel-group study
to evaluate the safety and efficacy of Lornoxicam in patients with mild to moderate probable
Alzheimer's Disease.
Study phase: II
Indication: Alzheimer´s Disease
Investigational product, dose schedule and route of administration: Lornoxicam (8 mg) tablets
to be taken orally two times daily (BID) for a period of 6 months.
Reference product, dose, schedule and route of administration: Placebo (8 mg) tablets to be
taken orally two times daily (BID) for a period of 6 months.